Vor Biopharma Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vor Biopharma Inc. (Nasdaq: VOR) on December 9, 2025, reporting events occurring on December 5, 2025. The filing details a significant corporate action regarding the repricing of outstanding stock options under the Company's 2021 Equity Incentive Plan and 2023 Inducement Plan.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation adjustments. Key equity-related figures include:
- Reduced Exercise Price: $8.18 per share (closing price on December 5, 2025).
- Total Repriced Shares: Approximately 5.2 million shares.
- Original Exercise Price Range: $17.80 to $47.60 per share.
Material Changes
The Board of Directors approved an option repricing effective December 5, 2025, reducing the exercise price of specific underwater options to the current market price of $8.18. This change applies to options held by continuing employees that were not previously repriced and had an original exercise price above $8.18. Additionally, the Chief Financial Officer's previously granted restricted stock units (RSUs) were cancelled and replaced with a new stock option award.
Guidance, Outlook, and Management Commentary
Management and the Board stated that the repricing was designed to retain and motivate key employees without incurring the stock dilution associated with new equity grants or the cash outflow of additional compensation. The filing includes specific conditions for the new pricing:
- Retention Period: Holders must remain in continuous service until the earliest of December 5, 2027, a Change in Control, or 30 days prior to the option's original expiration date.
- Early Exercise Penalty: If options are exercised before the end of the retention period, the original (higher) exercise price applies.
- Executive Specifics: CEO Jean-Paul Kress holds 4,164,831 repriced options (original price $17.80). CFO Sandy Mahatme received a new option award for 1,388,274 shares with an initial price of $17.80, reducing to $8.18 upon meeting retention milestones.
Investor Verification Checklist
- Verify the total number of shares underlying the repriced options (approx. 5.2 million) against the company's total authorized share count to assess potential dilution.
- Confirm the specific vesting schedules and expiration dates of the repriced options, as these were not altered but remain critical to valuation.
- Review the employment agreements of named executive officers to understand the "Continuous Service" definition and retention requirements.
- Check subsequent filings for any changes in the company's cash position or burn rate, as this filing does not disclose current liquidity levels.